Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of R-CVP vs R-CHOP vs R-FM in stage II-IV follicular lymphoma
2005-005406-24Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, vincristine, prednisone, doxorubicin and 2 more in follicular lymphoma (FL) (3 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoints: Time to treatment failure, Overall survival and 6 more. Started Mar 2007; status: completed.
02
Drugs
rituximabcyclophosphamidevincristineprednisonedoxorubicin
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2005-005406-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005406-24.